TAP Spectracef CAP sNDA Planned For October; Follows Aug. 29 Approval
This article was originally published in Pharmaceutical Approvals Monthly
Executive Summary
TAP's first planned labeling expansion for the cephalosporin antibiotic Spectracef (cefditoren pivoxil) will be an indication for community-acquired pneumonia, with an sNDA submission anticipated in October.